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ABSTRACT: The first total synthesis of caprazamycin A 
(1), a representative liponucleoside antibiotic, is described. 
Diastereoselective aldol reactions of aldehydes 12 and 25–
27, derived from uridine, with diethyl isocyanomalonate 13 
and phenylcarbamate 21 were investigated using thiourea 
catalysts 14 or bases to synthesize syn--hydroxyamino acid 
derivatives. The 1,4-diazepanone core of 1 was constructed 
using a Mitsunobu reaction, and the fatty acid side chain 
was introduced using a stepwise sequence based on model 
studies. Notably, global deprotection was realized under 
using palladium black and formic acid without hydrogenat-
ing the olefin in the uridine unit. 
Introduction 
Liponucleoside antibiotics are a class of natural products 
with structures comprising uridine attached to amino acids, 
namely 5’-C-glycyluridine, an aminoribose, and a fatty acid 
side chain. Examples include caprazamycins,(1) liposidomy-
cins,(2) muraymycins,(3) A-90289,(4) and sphaerimicins(5) 
(Figures 1 and 2). Several liponucleoside antibiotics inhibit 
bacterial translocase MraY, which is a peptide glycan en-
zyme.(6) In the biosynthetic pathway, MraY is located up-
stream of the enzyme targeted by -lactam antibiotics and 
glycopeptide antibiotics (such as vancomycin). Therefore, 
novel antibiotics targeting MraY are expected to have a 
broad antimicrobial activity spectrum, including against 
multi-drug resistant bacteria such as methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant S. 
aureus (VRSA). 
Caprazamycins were isolated from Streptomyces sp. 
MK730-62F2 by Igarashi and coworkers in 2003 (Figure 
1).(1) Structurally, these molecules possess a 1,4-
diazepanone, which is a seven membered ring containing 
two nitrogen atoms, retaining the common motif of several 
liponucleoside antibiotics. The biosynthesis of caprazamy-
cins was proposed through in vivo and in silico analysis of 
the biosynthetic gene cluster.(7) Recently, an enzyme catalyst 
that promotes an aldol-type condensation with glycine and 
uridine-5’-aldehyde to construct 5’-C-glycyluridine was 
identified.(8) Caprazamycins show  
Figure 1. Caprazamycins, caprazol, and CPZEN-45. 
 
Figure 2. Structures of representative liponucleoside antibiotics. 
  
Scheme 1. Retrosynthetic analysis of caprazamycin A (1) 
antibacterial activity against Mycobacterium tuberculosis, 
including the multi-drug resistant strain (MDR-TB), by inhib-
iting MraY as mentioned  above.(1) Through caprazamycin 
derivatization, Takahashi and coworkers developed CPZEN-
45, which exhibits more potent antibacterial activity, particu-
larly against extensively drug-resistant tuberculosis (XDR-
TB).(9) As MDR-TB and XDR-TB are resistant to at least four 
of the core anti-TB drugs, including isoniazid and rifampicin, 
they present a potential public health problem. Therefore, 
caprazamycins and CPZEN-45 are receiving attention as seed 
compounds for future effective antibiotic drugs. Owing to its 
important biological activity and complex structure, we ex-
pected a total synthesis of caprazamycins to provide not only a 
synthetic sample and route for synthetic analogs, but also an 
opportunity to develop new synthetic strategies.  
 
Synthetic plan 
When we began investigating the synthesis of liponucleoside 
antibiotics, the total synthesis of caprazamycins and liposido-
mycins had yet to be reported, although various synthetic 
studies towards liponucleoside antibiotics had been pub-
lished.(10–14) In 2008, Ichikawa, Matsuda, and coworkers 
achieved the first total synthesis of caprazol (2), which is a 
core structure in caprazamycins.(6e) In their synthesis, a Sharp-
less aminohydroxylation and reductive amination were key 
reactions for constructing the syn--hydroxyamino acid moie-
ty and 1,4-diazepanone core, respectively. After this landmark 
report, Shibasaki, Watanabe, and coworkers reported a total 
synthesis of caprazol (2) in 2013 based on a Cu-catalyzed dia-
stereoselective aldol reaction used to construct the syn--
hydroxyamino acid moiety.(13c) However, the introduction of a 
caprazamycin-type fatty acid side chain has not been reported. 
These preceding studies indicated that the synthesis of liponu-
cleoside antibiotics presented the following challenges: (i) 
Construction of the syn--hydroxyamino acid moiety, (ii) 
 formation of the 1,4-diazepanone core, and (iii) introduction 
of the fatty acid side chain. To achieve a total synthesis of 
caprazamycin A (1), fatty acid side chain 4 would need to be 
introduced to caprazol core 5 at the late stage because these 
substructures were expected to be unstable under acidic and 
basic conditions due to the presence of -acyloxyester and 
acyloxy acetal moieties (Scheme 1). Benzyl (Bn), ben-
zyloxymethyl (BOM), and benzyloxycarbonyl (Cbz) groups 
were selected as protecting groups for the caprazol core 5 that 
could be removed under mild conditions. The 1,4-diazepanone 
motif in 5 would be constructed through a Mitsunobu reac-
tion(15) of alcohol 6a, itself accessed from syn--
hydroxyamino acid derivative 10 thorough -selective glyco-
sylation with glycosyl fluoride 9(12e) and coupling with sec-
ondary amine 7a. To construct the syn--hydroxyamino acid 
moiety, we developed an asymmetric synthesis of trisubstitut-
ed oxazolidinones through the thiourea-catalyzed aldol reac-
tion of 2-isocyanatomalonate diester 13.(16,17) Extending this 
method, syn--hydroxyamino acid derivative 10, which is a 
protected 5’-C-glycyluridine, would be synthesized from al-
dehyde 12 through a diastereoselective aldol reaction with 13 
using thiourea catalysts 14, followed by ring opening of the 
resultant oxazolidinone 11a and decarboxylation. In this aldol 
reaction, the thiourea catalyst must precisely recognize a nu-
cleophilic site (aldehyde) to achieve high stereoselectivity, 
which is challenging owing to the presence of several func-
tionalities, including ether, imide, and N,O-acetal groups. The 
fatty acid side chain would be synthesized by coupling rham-
nose derivative 15, β-hydroxyester 16, and carboxylic acid 17 
(vide infra). In this report, we describe in full detail the first 
total synthesis of caprazamycin A, which was achieved by 
overcoming the three challenges described above.(18) 
 
Results and discussion 
1. Diastereoselective synthesis of syn--hydroxyamino acid 
moiety 
To investigate the diastereoselective aldol reaction, diethyl 
isocyanomalonate 13 was prepared from diethylaminomalo-
nate hydrochloride 20 using triphosgene following a literature 
procedure (Scheme 2).(19) As diethyl isocyanomalonate 13 
readily polymerizes in the presence of trace amounts of water, 
it was used immediately after preparation. When water was 
removed by Kugelrohr distillation, the distilled diethyl isocy-
anomalonate 13 could be stored for several weeks. Phenyl 
carbamate 21, which is much more stable than 13, was also 
prepared in 97% yield by treating 20 with phenyl chlorofor-
mate and sodium bicarbonate under Schotten–Baumann con-
ditions. 
 
Scheme 2. Preparation of isocyanate 13 and phenylcarbamate 21. 
 
Initially, the diastereoselectivity of the aldol reaction of al-
dehyde 12, prepared from a known protected uridine by IBX 
oxidation,(20) with diethyl isocyanomalonate 13 or phenylcar-
bamate 21 was examined in the absence of thiourea catalyst 
14a (Table 1). While the aldol reaction with isocyanate 13 
using 1,8-diazabicyclo(5.4.0)-7-undecene (DBU) as base (10 
mol%) afforded oxazolidinones 11a and 11b in 42% yield, no 
selectivity was observed (entry 1). Using Et3N or K2CO3 as 
base did not improve the selectivity (entries 2 and 3). Under 
these conditions, a small amount of byproduct 22 was ob-
tained through the reaction of products 11a and 11b with di-
ethyl isocyanomalonate 13. Therefore, less-reactive phenyl-
carbamate 21 was employed as a nucleophile. Treatment of 
aldehyde 12 with phenylcarbamate 21 (1.0 equiv.) and DBU 
(1.0 equiv.) in THF at room temperature gave a 1:2.2 mixture 
of desired oxazolidinone 11a and undesired isomer 11b in 
59% yield through phenylcarbamate addition and PhOH elim-
ination (entry 4).  
To control the selectivity through chelation, several addi-
tives were tested.(11v,21,22) Adding ZnCl2 did not affect the se-
lectivity (entry 5). The aldol reaction with LiBr (1.0 equiv.) 
resulted in a 56% yield with a 1:1.5 dr (entry 6). In this reac-
tion, a small amount of 23 was obtained from elimination of 
the uracil moiety. To reverse this diastereoselectivity, we ap-
plied the same conditions using (S,S)-thiourea catalyst 14a, 
which was developed for the asymmetric aldol reaction of 
aldehydes.(16) The reaction of 12 with diethyl isocyanomalo-
nate 13 in the presence of 14a (10 mol%) proceeded smoothly, 
affording desired oxazolidinone 11a as the major product 
(64%, 3.1:1 dr, entry 7). It was significant that the selectivity 
of this aldol reaction could be reversed using an organocata-
lyst. Both the yield and diastereoselectivity were improved 
(77%, 6.5:1 dr) using (S,S)-thiourea catalyst 14b (10 mol%) 
bearing a bulky tertiary amine moiety (entry 8). The amount 
of catalyst 14b could be reduced to 7 mol%, although this 
slightly decreased the diastereoselectivity. Interestingly, the 
formation of byproduct 22 was suppressed by reducing the 
amount of catalyst 14b. When the amount of catalyst was re-
duced to 5 mol%, the reaction proceeded slowly to give oxa-
zolidines 11a and 11b in 68% yield, but with 4.2:1 dr, and a 
small amount of starting  
 
 Table 1. Diastereoselective aldol reaction of aldehyde 12 with thiourea catalysts 14. 
 
 
material 12 was recovered (entry 10). Interestingly, the aldol 
reaction using (R,R)-thiourea catalyst 14b (10 mol%) gave 
undesired isomer 11b in 80% yield in a highly diastereoselec-
tive manner (>1:20 dr) (entry 11). These results indicated that 
the aldol reaction of aldehyde 12 with (R,R)-thiourea catalyst 
14b was a matched pair that afforded undesired isomer 11b. 
To explain this diastereoselectivity, a computational model 
study of this thiourea-catalyzed aldol reaction using benzalde-
hyde was conducted based on a DFT calculation (Scheme 3a, 
B3LYP/6-311+G(d,p)//B3LYP/6-31G(d) level).(23) The calcu-
lation suggested that transition state A was more favorable 
than transition state B, in which there was steric repulsion 
between the phenyl and isocyanate groups. Transition state C, 
which is another possible transition state towards undesired 
isomer 24b, was not more favorable than B, because C would 
be destabilized by steric repulsion between the tertiary amine 
and uracil moieties. Consequently, isocyanomalonate 13 
would approach from the Si face of benzaldehyde to give S-
isomer 24a. Indeed, this reaction gave S-isomer 24a in 87% 
yield with 88% ee.(16) Considering these results, the stereose-
lectivity of the reaction of aldehyde 12 with 13 using thiourea 
catalyst 14 was rationalized using the following reaction 
mechanism (Scheme 3b). Initially, thiourea catalyst 14 recog-
nizes the two carbonyl groups of isocyanomalonate 13 
through hydrogen bonding. The protonated tertiary amine 
moiety of thiourea catalyst 14 interacts with the carbonyl 
group of aldehyde 12 through hydrogen bonding to afford 
transition state D rather than transition state E. Subsequent 
cyclization of the resultant alcohol with isocyanate gave de-
sired oxazolidinone 11a as the main product. 
We also investigated the aldol reaction of the related alde-
hydes 25–27,(24–26) in which two hydroxyl groups were pro-
tected as benzyloxymethyl (BOM), triisopropylsilyl (TIPS), 
and t-butyldimethylsilyl (TBS) ethers instead of isopropy-
lidene acetal (Table 2). When aldehyde 25 was treated with 
isocyanomalonate 13 and (S,S)-thiourea 14a in toluene at 0 °C 
to room temperature, the reaction proceeded to give desired 
product 28a in 55% yield with >9:1 dr (entry 1). In contrast, 
when (R,R)-thiourea catalyst 14b was used in an attempt to 
reverse the diastereoselectivity, diastereomer 28b was ob-
tained as a minor product (2:1 dr, entry 2). As such diastere-
oselectivity was not obtained using aldehyde 12 bearing an 
isopropylidene acetal, it was assumed that this selectivity was 
derived from the bulkiness of the hydroxy protecting groups 
and/or the conformation of aldehyde 25.(27) Therefore, the 
reaction was also performed without chiral thiourea catalyst. 
When potassium carbonate was used as a basic catalyst, the 
reaction proceeded with high diastereoselectivity (entry 3). 
  
Scheme 3. (a) Computational study of thiourea-catalyzed aldol reaction using benzaldehyde and catalyst 14a, based on B3LYP/6-311+G(d,p)//B3LYP/6-31G(d) 
(in a vacuum) using Gaussian 09; (b) rationalization of diastereoselectivity of thiourea-catalyzed aldol reaction of aldehyde 12
 Table 2. Diastereoselective aldol reaction of aldehydes 25–27 with diethyl isocyanomalonate 13 and phenylcarbonate 21. 
 
 
Scheme 4. Computational study of diastereoselective aldol reaction of aldehyde 27 with isocyanate 13, based on B3LYP/6-311+G(d,p)//B3LYP/6-31G(d) (in a 
vacuum) using Gaussian 09. 
 The reaction of aldehyde 26, bearing TIPS groups, with iso-
cyanomalonate 13 gave desired oxazolidinone 29a as the ma-
jor product with 4.6:1 dr. The selectivity was improved by 
using a tertiary amine, with diisopropylethylamine (DIPEA) 
proving particularly effective (entries 5 and 6). Furthermore, 
we attempted reacting 26 with phenylcarbamate 21, which 
was easier to handle than isocyanomalonate 13. Although 1 
equiv. of potassium carbonate was required, this reaction pro-
ceeded smoothly to give desired oxazolidinone 29a in 62% 
yield with 13:1 dr (entry 7). These conditions using 21 could 
be applied to a large-scale synthesis from aldehyde 27 bearing 
a TBS group (17-g scale), which could be readily prepared 
from uridine. The desired oxazolidinone 30a was obtained in 
84% yield with excellent selectivity (entry 8). To explain this 
diastereoselectivity, we estimated an activation energy for the 
reaction of aldehyde 27 with isocyanate 13 using DFT calcula-
tion at the B3LYP/6-311+G(d,p)//B3LYP/6-31G(d) level 
(Scheme 4). (23) The results indicated that the activation energy 
for transition state F, which affords desired adduct 31a, was 
2.10 kcal/mol lower than that of transition state G, which af-
fords undesired adduct 31b. In transition state G, there is ste-
ric repulsion between an ester group in 13 and a silyl group in 
27, which would make transition state F preferable. Resulting 
adducts 31a and 31b would immediately cyclize to give oxa-
zolidinones 30a and 30b, respectively. Therefore, desired oxa-
zolidinone 30a would be the major product.  
Obtained aldol adducts 11a, 28a, and 30a were converted 
into syn--hydroxyamino acid derivatives 10, 38, and 39 
(Scheme 5). Selective monohydrolysis of 11a, 28a, and 30a 
followed by decarboxylation gave thermodynamically stable 
trans-oxazolidinones 32–34, respectively. Transesterification 
of 32–34 using a tetranuclear zinc cluster(28) to afford methyl 
esters 35–37 was essential for concise oxazolidinone ring-
opening.  
Scheme 5. Synthesis of syn--hydroxyamino acid derivatives 10, 38, and 39. 
 
 
After introducing a p-nitrobenzenesulfonyl (pNs) group, the 
oxazolidinone ring was opened by treatment with NaOMe to 
afford syn--hydroxyamino acid derivatives 10, 38, and 39 in 
good yields. Protected compounds 10, 38 and 39 are useful 
intermediates for the synthesis of liponucleoside antibiotics. 
Indeed, we achieved the total synthesis of CPZEN-45 (3) from 
intermediate 39 in 2016.(14a) 
2. Introduction of a fatty acid side chain using model 1,4-
diazepanone 
Although Shibasaki, Watanabe, and coworkers had reported 
a synthesis of the fatty acid side chain of caprazamycin B,(13d) 
the introduction of fatty acid side chain 4 onto a diazepanone 
ring had not been reported before we began this synthetic 
study. Presumably, this was due to the fatty acid side chain 
containing an unstable -acyloxycarboxylic acid structure, 
meaning that -elimination and acyl group rearrangement 
might occur under basic conditions (Figure 3).  
 
Figure 3. Predictable side-reactions when introducing the fatty-acid side 
chain of caprazamycin A (1) 
Furthermore, several side reactions on the diazepanone ring, 
such as epimerization, -elimination, and retro-aldol reactions, 
were expected. Therefore, we initially planned to establish a 
synthetic route toward model substrate 40 by introducing fatty 
acid side chain 4 onto diazepanone 41 (Scheme 6).  
Simple diazepanone 41 would be synthesized by coupling 
anti--hydroxy amino acid derivative 7b with carboxylic acid 
43, derived from serine,(29) followed by an intramolecular 
Mitsunobu reaction. To prevent undesired side reactions of the 
-hydroxy amino acid moiety under Mitsunobu conditions, 
determining appropriate reaction conditions and protecting 
groups was important. Fatty acid side chain 4 would be syn-
thesized by coupling known rhamnose derivative 15(30) with 
carboxylic acid 17, followed by condensation with -hydroxy 
ester 16 (Scheme 1). Intermediates 16 and 17 would be pre-
pared by the Noyori asymmetric reduction of keto ester 18 and 




Scheme 6. Planned synthetic route for model diazepanone 41 bearing a fatty 
acid side chain. 
The synthesis started with known diol 45, prepared from L-
(+)-diethyltartrate in a five-step transformation (Scheme 7).(33) 
Selective silylation of the primary alcohol followed by azide 
reduction gave an amine that was then protected as the corre-
sponding pNs-amide. Resultant alcohol 46 was converted to 
anti--hydroxyamino acid derivative 7b through silylation of 
the secondary alcohol, introduction of a methyl group, and 
removal of the pNs group. Compound 7b was coupled with 
carboxylic acid 43, derived from L-serine,(14c,29) using 
Ghosez’s reagent(34) to afford compound 47 in 57% yield. Af-
ter selective removal of the TBS group by treatment with 10-
camphorsulfonic acid (CSA) in MeOH–CH2Cl2 (2:3), the 
Mitsunobu reaction(15) of obtained alcohol 42 using diethyl 
azodicarboxylate (DEAD) and PPh3 proceeded smoothly to 
give 1,4-diazepanone 48 in 92% yield.  
Previous studies reported that both the hydroxy group and 
ester on the 1,4-diazepanone ring were oriented in pseudo-
axial positions.(11u,v,y) In contrast, our DFT calculation sug-
gested that the siloxy group and ester on 1,4-diazepanone 48 
were oriented in pseudo-equatorial and pseudo-axial positions, 
respectively (Figure 4, conformation X). Conformation X was 
more stable than conformation Y, in which both substituents 
were oriented in pseudo-axial positions, presumably owing to 
the presence of a bulky substituent (pNs group) on the nitro-
gen atom. The coupling constant of 3.3 Hz observed between 
Ha and Hb did not contradict predicted conformation X. Com-
pound 48 was converted to secondary amine 49 in 90% yield 
by treatment with PhSH and K2CO3. As a model study for 
introducing the side chain, compounds 41a and 41b were pre-
pared by introducing methyl and 2,2,2-
trichloroethoxycarbonyl (Troc) groups, respectively. In the 
synthesis of 41a, an ,-unsaturated ester 50 was obtained as 
byproduct owing to the basic workup after treatment with 
aqueous hydrogen fluoride (HF). Consequently, the isolated 
yield of 41a was low. 
Scheme 7. Synthesis of 1,4-diazepane 41 using a Mitsunobu reaction. 
 
 
Figure 4. Possible conformations X and Y of compound 48, calculated using 
Gaussian ‘09 at the B3LYP/6-31G(d) level of theory (DFT). 
 
 Next, the synthesis of a fatty acid side chain 4 started with 
the desymmetrization of 3-methyl glutaric acid anhydride 19 
using a cinchona alkaloid catalyst developed by Song and 
coworkers (Scheme 8).(32) The resulting carboxylic acid 17 
(92% ee) was coupled with L-rhamnose derivative 15(30) 
through acid chloride formation to give ester 51. After sepa-
rating a small amount of the undesired diastereomers, a benzyl 
group was removed by hydrogenolysis in the presence of Pd/C 
to afford carboxylic acid 52. -Hydroxybenzyl ester 16 was 
synthesized by Noyori asymmetric reduction(31) of known -
ketoester 18,(35) which was prepared from myristoyl chloride 
53. Ester 16 was condensed with carboxylic acid 52 under 
Yamaguchi conditions.(13d) Protected fatty acid side chain 54 
was successfully converted into the fatty acid fragment of 
caprazamycin A (4), which had the same stereochemistry as 
the natural product, in the presence of Pd/C under a hydrogen 
atmosphere. 
Scheme 8. Synthesis of fatty acid side chain 4. 
With fatty acid side chain 4 and model 1,4-diazepanones 
41a and 41b in hand, our attention turned to introducing the 
fatty acid side chain onto the 1,4-diazepanone core. Initially, 
the direct coupling of 4 onto model 1,4-diazepanone 41a was 
investigated (Scheme 9). When using EDCI, DCC, or PyBOP, 
the reaction gave a complex mixture.(36) To avoid undesired -
elimination of the -alkoxyester unit, condensation with 2,4-
dimethoxybenzyl (DMB)-protected -hydroxy carboxylic acid 
55a was attempted.(37) However, reactions using EDCI, DCC, 
or PyBOP did not afford desired coupling product 56, with 
aldehyde 57 observed as a byproduct produced by a retro-
aldol reaction. In contrast, the reaction of Troc-protected 1,4-
diazepanone 41b with DMB-protected -hydroxy carboxylic 
acid 55a using EDCI proceeded smoothly, giving desired cou-
pling product 58a in excellent yield. For subsequent transfor-
mations, including protecting group removal, triethylsilyl 
(TES)-protected -hydroxy carboxylic acid 55b was em-
ployed in this condensation reaction, affording desired ester 
58b in 62% yield. These results indicated that compound 41b 
was more reactive than 41a in this transformation, despite 
having the same conformation. Our DFT calculations suggest-
ed that the enhanced reactivity of 41b might be due to the 
presence of a hydrogen bond between the hydroxy and Troc 
groups (Figure 5). 
Ester 58b was treated with zinc and AcOH to reductively 
remove the Troc group (Scheme 9). The resultant secondary 
amine was subjected to reductive amination followed by re-
moval of the TES group to furnish N-methylated compound 
59 in 66% yield. The glutaric monoester unit 52 was then suc-
cessfully introduced to secondary alcohol 59 under Yamagu-
chi conditions. This stepwise method for introducing the fatty 
acid side chain was robust owing to no decomposition of the 
unstable structure and no epimerization. Therefore, this route 
would be applicable to introducing the fatty acid side chains 
of not only caprazamycins, but related liponucleoside antibiot-
ics such as liposidomycins and sphaerimicins.  
3. Total synthesis of caprazol (2) and caprazamycin A (1) 
With an established route for introducing the fatty acid side 
chain in hand, we next focused on constructing a 1,4-diazepanone 
core bearing amino-ribose and uridine moieties and introduc-
ing the side chain to achieve a total synthesis of caprazamycin 
A. Glycosylation of syn--hydroxyamino acid derivatives 10 
with compound 9 proceeded in a β-selective manner under the 
conditions reported by Matsuda and Ichikawa (Scheme 10).(12) 
Reduction of the azide in coupling product 60, followed by 
protection of the resulting amine with a Cbz group and methyl 
ester hydrolysis afforded carboxylic acid 8. Carboxylic acid 8 
was coupled with anti--hydroxyl acid derivative 7a, in which 
the secondary alcohol was protected as a TBS ether, using 
Ghosez’s reagent(34) via acid chloride formation. Selective 
TBS group removal from the primary alcohol of 61a gave 
cyclization precursor 6a. To investigate the Mitsunobu cy-
clization, compound 6b was also synthesized from carboxylic 
acid 8 and anti--hydroxyl acid derivative 7b using a similar 
sequence. No -elimination or epimerization were observed in 
these transformations. 
 Scheme 9. Introduction of fatty acid onto diazepanone 41. 
 
Figure 5. Conformations of compounds 41a and 41b calculated by Gaussian 
‘09 at the B3LYP/6-31G(d) level of theory (DFT). 
Next, we focused on construction the 1,4-diazepanone skel-
eton using a Mitsunobu reaction. Initially, the intramolecular 
Mitsunobu reaction of compound 6b, bearing a secondary 
alcohol protected as a p-methoxybenzyl (PMB) ether, was 
attempted. Although the cyclization of simple model com-
pound 42 proceeded smoothly (Scheme 7), the reaction of 6b 
did not give desired cyclization product, even when diethyl 
azodicarboxylate (DEAD) or diisopropyl azodicarboxylate 
(DIAD) were employed in the presence of PPh3. Mass spec-
trometry analysis indicated that byproduct 63 was generated in 
this reaction through an intermolecular SN2 reaction with hy-
drazine-1,2-dicarboxylate produced by the reduction of DEAD 
or DIAD. These results indicated that the intermolecular SN2 
reaction of intermediate 64 was preferred over the desired 
intramolecular SN2 reaction. To suppress this side reaction, we 
employed sterically bulkier substrate 6a bearing a TBS group 
adjacent to the primary alcohol. As expected, the reaction with 
DIAD afforded cyclized product 62 in 70% yield. Furthermore, 
using di-tert-butyl azodicarboxylate (DBAD), which is bulkier 
than DIAD, improved the yield to 75%. By increasing the 
bulkiness of both the substrate and reagent, the undesired in-
termolecular SN2 reaction was suppressed to afford the 1,4-
diazepanone product.  
Before introducing the fatty acid side chain, cyclized prod-
uct 62 was converted into protected caprazol 5 to facilitate the 
final global deprotection (Scheme 10). After removing the 
pNs group, a Troc group was introduced to afford compound 
65 in 58% yield over two steps. Two acetal groups were care-
fully hydrolysed under acidic conditions and the obtained 
tetraol was converted to a Cbz carbonate, followed by treat-
ment under acidic conditions to remove the TBS group. To 
confirm the stereochemistry of protected caprazol 5, it was 
converted to caprazol (2). Troc group removal followed by 
reductive amination gave a tertiary amine, followed by treat-
ment with Pd black in the presence of formic acid to give 
caprazol (2), which had spectra data identical to those reported 
previously.(12d,e,13c) 
  
Scheme 10. Investigation of Mitsunobu reaction and synthesis of caprazol (2). 
 
To complete the first total synthesis of caprazamycin A (1), 
we carefully applied model studies to couple protected capra-
zol 5 with fatty acid side chain 55b (Scheme 11). Condensa-
tion of 5 with 55b using EDCI successfully proceeded to af-
ford the desired acylated product without undesired side reac-
tions, such as -elimination, epimerization, and retro-aldol 
reaction on the 1,4-diazepanone. After removing the Troc 
group in the presence of zinc and acetic acid, the resultant 
carbamic acid intermediate was treated with acetic acid to give 
compound 66 via decarboxylation. Reductive amination of 
secondary amine 66 was followed by TES group removal to 
afford corresponding alcohol 67. Yamaguchi conditions(13d) 
were applied to introduce the fatty acid side chain 52 contain-
ing rhamnose. Although the reaction  
  
Scheme 11. The first total synthesis of caprazamycin A (1). 
 
afforded protected caprazamycin A (68), byproduct 69 was 
readily formed through -elimination under these conditions. 
Therefore, the amounts of Et3N and 4-dimethylaminopyridine 
(DMAP) were reduced, and the reaction time was shortened. 
As a result, protected caprazamycin A (68) was obtained in 
64% yield. 
Finally, conditions for the global deprotection of five Cbz, 
one BOM, and one Bn groups in the protected caprazamycin 
A (68) while avoiding reduction of the uracil olefin were in-
vestigated. Using 10% Pd/C under a hydrogen atmosphere 
removed the protecting groups, but also resulted in olefin hy-
drogenation. Although various palladium (Pd) catalysts, in-
cluding 5% Pd/C, Pd/C(en), and Pd(OH)2/C, in the presence 
of various hydrogen sources (H2, cyclohexadiene, and formic 
acid) were examined, none were able to suppress olefin reduc-
tion. In contrast, treatment with EtOH/formic acid (20:1, v/v) 
in the presence of Pd black resulted in a near-quantitative 
clean deprotection without olefin reduction. After careful neu-
tralization, the spectral data, including NMR (DMSO-d6/D2O, 
20:1) and HRMS data, of the synthetic sample were identical 
to those of the natural product.(1) Therefore, the first total syn-
thesis of caprazamycin A (1) was successfully accomplished. 
The NMR spectra of caprazamycin A (1) were concentration- 
and pKa-dependent (Scheme 12). When NMR spectra of 1 
were measured using DMSO-d6/D2O/DCO2D (20:1:1), the 
carboxylic acid -proton in 1 was shifted downfield compared 
with that measured in 
 
Scheme 12. 1H NMR spectrum of caprazamycin A (1). 
 DMSO-d6/D2O (20:1). This indicated that caprazamycin A 
was in zwitterion form in DMSO-d6/D2O, but had a proto-
nated carboxylic acid in the presence of formic acid. 
 
Conclusions 
We have developed a diastereoselective aldol reaction of 
diethyl isocyanomalonate 13 and phenylcarbamate 21 for 
the synthesis of -hydroxy amino acid derivatives. Thiou-
rea catalyst 14 effectively obtained the desired 5’S-isomer 
11a in the aldol reaction of aldehyde 12 bearing an iso-
propylidene acetal moiety. The resultant aldol products 
were readily converted into syn--hydroxy amino acid de-
rivatives 10, 38, and 39 bearing several protecting groups. 
The 1,4-diazepanone core structure of caprazamycin A was 
obtained using a Mitsunobu reaction. A synthetic route for 
introducing a fatty acid side chain was established using a 
stepwise sequence. Finally, we achieved the first total syn-
thesis of caprazamycin A by identifying conditions for 
global deprotection without hydrogenation of the olefin in 
the uridine unit. These results and the established synthetic 
route will guide the synthesis of related liponucleoside an-
tibiotics bearing fatty acid side chains, including liposido-
mycins and spaerimicin A, and investigations into the syn-
thesis of a related natural product are currently underway in 
our laboratory. 
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